Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
Mingyue Cai, Wensou Huang, Wei Liang, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 920-930
Closed Access | Times Cited: 9

Showing 9 citing articles:

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
Xiaoyang Hong, Yongjian Guo, Wenbo Shi, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Yuhang Chen, Shengyuan Dai, Chien‐shan Cheng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 5
A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor
Saifeng Li, Qin Wen, Wen-wu Huang, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy
Fei-Yu Zhao, Xiaoming Zhang, Niansong Qian
World Journal of Gastroenterology (2025) Vol. 31, Iss. 10
Closed Access
Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)
Wei Gao, Zhao-Long Pan, Zhao Xiao-hui, et al.
EClinicalMedicine (2025) Vol. 83, pp. 103217-103217
Open Access
Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies
Yusra Zarlashat, Hafiz Salman Mushtaq, Linh Pham, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6830-6830
Open Access | Times Cited: 2
Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Tong Liu, Guorui Meng, Shihui Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era
Ugo Testa
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 9, pp. 803-827
Open Access
ALBI Grade Analyses of TACE Combined with Anti-Angiogenesis Therapies Plus PD-1 Inhibitors versus Anti-Angiogenesis Therapies Plus PD-1 Inhibitors in Advanced HCC
Xin Hong, Di Hu, Wen‐Jie Zhou, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 2505-2514
Open Access
Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
Feng Han, Xiaohan Wang, Chenzhou Xu
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 7, pp. 3308-3320
Open Access
Page 1

Scroll to top